Related Experiment Video
Updated: Mar 18, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the
Eva De Mol1, R Bryn Fenwick1, Christopher T W Phang1
1Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology , Baldiri Reixac 10, 08028 Barcelona, Spain.
Abstract:
Castration-resistant prostate cancer is the lethal condition suffered by prostate cancer patients that become refractory to androgen deprivation therapy. EPI-001 is a recently identified compound active against this condition that modulates the activity of the androgen receptor, a nuclear receptor that is essential for disease progression. The mechanism by which this compound exerts its inhibitory activity is however not yet fully understood. Here we show, by using high resolution solution nuclear magnetic resonance spectroscopy, that EPI-001 selectively interacts with a partially folded region of the transactivation domain of the androgen receptor, known as transactivation unit 5, that is key for the ability of prostate cells to proliferate in the absence of androgens, a distinctive feature of castration-resistant prostate cancer. Our results can contribute to the development of more potent and less toxic novel androgen receptor antagonists for treating this disease.
Insights
A new compound, EPI-001, targets a specific part of the androgen receptor (AR) in castration-resistant prostate cancer. This interaction may block AR activity, offering a new strategy for treating advanced prostate cancer.
Area of Science:
- Molecular biology
- Oncology
- Biochemistry
Background:
- Castration-resistant prostate cancer (CRPC) is a lethal progression of prostate cancer.
- CRPC is characterized by refractoriness to androgen deprivation therapy (ADT).
- The androgen receptor (AR) is crucial for CRPC progression.
Purpose of the Study:
- To elucidate the mechanism of action of EPI-001, a novel compound targeting CRPC.
- To investigate the interaction between EPI-001 and the androgen receptor.
- To identify potential therapeutic targets for CRPC treatment.
Main Methods:
- High-resolution solution nuclear magnetic resonance (NMR) spectroscopy was employed.
- The study focused on the interaction between EPI-001 and the transactivation domain of the androgen receptor.
Main Results:
- EPI-001 selectively interacts with transactivation unit 5 (TAU5) within the AR transactivation domain.
- TAU5 is a partially folded region critical for prostate cancer cell proliferation in the absence of androgens.
- This interaction suggests a novel inhibitory mechanism for EPI-001.
Conclusions:
- EPI-001's selective binding to AR TAU5 provides mechanistic insight into its anti-cancer activity.
- The findings support the development of novel AR antagonists for CRPC.
- Targeting AR TAU5 may lead to more potent and less toxic therapies for advanced prostate cancer.
